An analysis of changes to NHS spending on primary and secondary care caused by hypothetical new medicines that slow the development of age-related multimorbidity.
Publications / Articles
Publications came from funded project or UK SPINE core partner
This document, produced in collaboration with colleagues at the Medicines Discovery Catapult, a UK SPINE partner, is a guide to established best practice in drug discovery with a focus on interrogating aetiology of age-associated multimorbidity. Complementing the drug discovery roadmap, case studies drawn from recent clinical trials illustrate regulatory strategies for such interventions.
Yes
The study identifies the common risk factors that increase the likelihood of individuals developing not only one but multiple non-communicable diseases, which include cardiovascular disease, cancer, chronic respiratory disease and diabetes.
No
To inform the case for continued public funding for shared best practice, capability, capacity and collaboration in university commercialisation
Yes
Reducing the burden of late-life morbidity requires an understanding of the mechanisms of ageing-related diseases (ARDs), defined as diseases that accumulate with increasing age. This has been hampered by the lack of formal criteria to identify ARDs. Here, we present a framework to identify ARDs using two complementary methods...
No
Physiology is the science of life, and research in physiology helps us to understand how the body works in health, what goes wrong in disease, and how it responds and adapts to the challenges of everyday life.
Yes
Concerted action is required in order to increase the number of years spent in good health in old age. Health services should be coordinated to better treat people with multiple age-related illnesses, and technology and services should be deployed more widely to support independent living in old age. More effective public health advice and strategic government interventions can support life-long healthy living. Recent scientific discoveries reveal underlying processes of ageing, and the UK could play a leading role in developing treatments to address the root causes of age-related illnesses.
No
Human lifespans are increasing with advances in medicine, but the economic value of these gains are poorly understood. Based on U.S. data, we show a compression of morbidity that improves health is more valuable than further increases in life expectancy. However, economic gains to better health diminish unless longevity also improves.
No
Commentary on ageing, gerorprotectors and COVID-19.
Yes
On 13 – 14 February 2020, the Royal Society and the Academy of Medical Sciences hosted a conference on healthy ageing. The conference centred around the UK Government’s Healthy Ageing Grand Challenge of achieving five extra years of healthy older age by 2035, benefitting people from all backgrounds.
Patients with multimorbidities have shorter life expectancy and their clinical management is more complex and expensive for healthcare systems currently focused on treating single diseases. Given that age is the major risk factor for multimorbidity, the challenge of treating these patients will only increase in coming years. This paper reviews the case for targeting the core processes that drive the ageing phenotype as a novel pharmaceutical approach to multimorbidity. Although trials currently focus on repurposed drugs, this article proposes several novel targets that would more specifically target ageing processes and thereby reduce multimorbidity and polypharmacy in future generations.
Yes
A report that explains why longer, more productive lives will mean big changes to the old rules of aging.
A report that identifies areas where new approaches to housing and homes can be harnessed to improve the lives of older members of society, and the steps that need to be taken in order to unlock their potential.
A report written by the all-party parliamentary group for longevity containing policy recommendations to achieve 5 extra healthy years of life by 2035.
Yes
A short report on the ‘team science’ approach to target the disease clusters of ageing.
Yes
The EBMultimorbidity project focusses on early recognition, screening and treatment of multimorbidity to reduce the morbidity and minimise the risks to individuals while improving their quality of life and reducing costs to the healthcare system.
Yes
A platform aims to join-up and share helpful resources relevant to research on the global health challenge of multimorbidity. This platform is maintained by the Academy of Medical Sciences, in conjunction with the Medical Research Council (MRC), National Institute for Health Research (NIHR), and Wellcome.
A comprehensive report detailing the economic state of the pharmaceutical industry over the past 10 years written by Deloitte.
A Blog written by Dawn Moody and David Bramley about multimorbidity. They take a look at the adverse impact this can have upon individual quality of life and examine its association with higher mortality, adverse drug events and greater use unplanned care.
The UK SPINE midterm report detailing achievements until October 2019.
Yes
A case study of the UK SPINE.
Yes